India braces for Omicron with boosters and Covid pill

2 January 2022

As another wave of coronavirus infections swamp India, the country has stepped up its efforts to fight the disease and has cleared two new vaccines and one anti-COVID drug for restricted use.

Lockdown-like curbs and night curfews have made a comeback in several states amid the rising Omicron threat, with cases rising to 1,431 of the fast-spreading Omicron variant, and the country witnessing a 35% jump in new Covid cases, reports The Pharma Letter’s India correspondent.

The last week of 2021 saw India adding two more vaccines to its kitty with Corbevax and Covovax receiving Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK